Infertility Devices Market is well-positioned for expansion with new-facility openings of Invitae Corporation and The Cooper Companies to bode rising demand for fertility testing

 

Increasing infertility rate among numerous couples as well as single women are stimulating demand for the infertility devices market. As per the Centers for Disease Control and Prevention (CDC), in 2020, about 6 percent of the U.S. women aged 15-44 years were unable to conceive a baby after one year of marriage. Similarly, changing lifestyles, increasing consumption of tobacco and alcohol, and rising investments in the healthcare sector are all the driving factors in expansion of the Infertility Devices Market. In April 2021, the American fertility solution, Carrot Fertility, collaborated with a digital fertility service for males, Legacy, Inc., for providing access to male fertility tests.

Yes. About 6% of married women aged 15 to 44 years in the United States are unable to get pregnant after one year of trying (infertility). Also, about 12% of women aged 15 to 44 years in the United States have difficulty getting pregnant or carrying a pregnancy to term (impaired fecundity).

On the geographical front, Asia Pacific is likely to experience a rapid surge in the infertility devices market owing to the growing infertility cases in this region. The rising number of couples opting for ARTs (Assisted reproductive technologies), along with advanced technology that provides fertility clinics, hospitals, and equipment manufacturers with opportunities to extend the business presence of the companies operating in this market. Likewise, the North American region is poised to grab a major chunk of share in the infertility devices market. The high prevalence of infertility, raising understanding of fertility tests among women, the rising age of first-time pregnancies in women, and the convenient availability of ovulation and fertility monitors via e-commerce websites are all contributing to this region's wide share. In April 2019, the Cooper Companies Inc., acquired The LifeGlobal Group, a major provider of IVF (in-vitro fertilization) devices to broaden its fertility solution facilities.

Although, the higher costs of IVF (in-vitro fertilization) procedure and the chance of infections associated with it are the refraining factors in the expansion of the infertility devices market. The needed treatment methods are still out of reach for many due to high costs, and country-specific regulatory challenges are significant roadblocks to the infertility testing and treatment sector. Many infertile families are now unable to afford the care.

FSH (follicle stimulating hormone), HCG (Human chorionic gonadotropin) hormone, and LH (luteinizing hormone) are examples of reproductive hormones that can be measured using infertility devices and rapid pregnancy testing kits. Rapid fertility testing kits can be used to detect sperm count in males. Whereas these rapid fertility testing kits are used in females to verify menopause or to determine the particular day of ovulation. These tests use immunoassay methods to adjust the color of the sample. The type of instrument determines when a blood or urine sample can be used for the test, and only a limited amount of sample is used for the test.